LEVOCETIRIZINE TAD 5 mg urticaria film-coated tablets
Active substance: Levocetirizine dihydrochloride
Areas of application: For the treatment of symptoms (symptoms) such as: allergic rhinitis (including persistent allergic rhinitis); Hives (urticaria). If you don't feel better or even worse after 3 days, contact your doctor.
Warnings: For use in adults and children from 6 years of age. Medicinal product contains lactose. Only take the preparation after consulting a doctor if there is an intolerance to certain sugars.
For LEVOCETIRIZINE 5 mg urticaria information on risks and side effects, read the package insert and ask your doctor or pharmacist.
Levocetirizine TAD ®- overcome your allergy
Levocetirizine TAD ® is a second generation antihistamine for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and urticaria.
Levocetirizine TAD ® is a fast-acting drug with long-lasting effects on the relief of allergic symptoms in allergic rhinitis and urticaria (hives). 1
The TAD ® in LevocetirizineThe active ingredient levocetirizine dihydrochloride can block the histamine receptors and thus reduce typical allergy-related symptoms such as sneezing, runny nose, itchy nose and itchy eyes. As a second generation antihistamine, it has less or no sedating effect. 2
Finally awake through the allergy season with Levocetirizine TAD ® :
• Relieves the allergic symptoms within the first 30 minutes after ingestion3
• Less tiredness / drowsiness than with 1st generation antihistamines (e.g. cetirizine) 2
• Better effect than cetirizine 4
• only one tablet required per day 1
• for the relief of very itchy rashes in chronic hives
LEVOCETIRIZINE 5 mg for urticaria well tolerated
• already suitable for children from 6 years of age
• little potential for interactions with other drugs 1
take one film-coated tablet once a day.
Children from 6 years and adults.
The recommended dose is 1 tablet a day and can be taken with or without food.
1 : Instructions for use Levocetirizine TAD ® , as of May 2019.
2 : Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006; 66 (18): 2309-19.
3: Simons FE. Am J Med. 2002; 113 (9A): 38S – 46S
4 : Kłos K, Kruszewski J, Kruszewski R, Sułek K. Pol Merkur Lekarski 2006; 21 (125): 449-53.